Molecular targeted agents as second-line treatment for hepatocellular carcinoma: a meta-analysis and review

Jung Han Kim; Bum Jun Kim; Hyun Joo Jang; Jin Lee

doi:10.18632/oncotarget.21454

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Meta-Analysis:

Molecular targeted agents as second-line treatment for hepatocellular carcinoma: a meta-analysis and review

Jung Han Kim _, Bum Jun Kim, Hyun Joo Jang and Jin Lee

PDF | HTML | How to cite

Oncotarget. 2017; 8:102321-102327. https://doi.org/10.18632/oncotarget.21454

Metrics: PDF 1050 views | HTML 1484 views | ?

Abstract

Jung Han Kim1, Bum Jun Kim1,2, Hyun Joo Jang3 and Jin Lee3

1Division of Hemato-Oncology, Department of Internal Medicine, Kangnam Sacred-Heart Hospital, Hallym University Medical Center, Hallym University College of Medicine, Seoul 07441, Republic of Korea

2Department of Internal Medicine, National Army Capital Hospital, The Armed Forces Medical Command, Sungnam 13574, Republic of Korea

3Division of Gastroenterology, Department of Internal Medicine, Dongtan Sacred-Heart Hospital, Hallym University Medical Center, Hallym University College of Medicine, Hwasung 18450, Republic of Korea

Correspondence to:

Jung Han Kim, email: [email protected]

Hyun Joo Jang, email: [email protected]

Keywords: hepatocellular carcinoma, targeted agent, second-line treatment, meta-analysis

Received: August 02, 2017 Accepted: September 20, 2017 Published: October 03, 2017

ABSTRACT

It is unclear whether targeted agents can produce survival advantage in patients with advanced HCC previously treated with sorafenib. We performed this meta-analysis of randomized trials and reviewed clinical outcomes of molecular targeted agents in the second-line treatment for advanced HCC. A systematic computerized search of the electronic databases PubMed, Embase, Google Scholar, and Cochrane Library (up to May 2017) was carried out. From six studies, 2,388 patients were included in the meta-analysis. Almost all patients were treated with sorafenib as first-line therapy. Compared with placebo, targeted agents significantly improved time-to-progression (hazard ratio = 0.62, 95% confidence interval: 0.49–0.78, P < 0.0001). In terms of overall survival, targeted therapy tended to improve prognosis (hazard ratio = 0.86, 95% confidence interval: 0.74–1.01, P = 0.06). In conclusion, this meta-analysis indicates that molecular targeted agents have a potential to improve prognosis after failure of first-line treatment with sorafenib in patients with advanced HCC.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 21454

Publication Alerts

Meta-Analysis:

Molecular targeted agents as second-line treatment for hepatocellular carcinoma: a meta-analysis and review

Abstract